ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction

Guiqing Huang, Sheryl Krig, David Kowbel, Hongmei Xu, Bill Hyun, Stas Volik, Burt G.F. Feuerstein, Gordon B. Mills, David Stokoe, Paul Yaswen, Colin Collins

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Chromosome 20q13.2 is amplified in 20-30% of early-stage breast tumors and is associated with poor prognosis. Detailed mapping of the amplified region using molecular cytogenetics, positional cloning and genomic sequencing culminated in a detailed molecular description of the candidate oncogene ZNF217. ZNF217 proteins resemble Kruppel-like transcription factors, localize predominately to the nucleus and associate with proteins involved in transcriptional repression. The findings that ZNF217 can immortalize human mammary epithelial cells and that its amplification is associated with poor prognosis suggest that it may play roles in both early- and late-stage breast cancer. We present evidence that ZNF217 can attenuate apoptotic signals resulting from telomere dysfunction as well as from doxorubicin-induced DNA damage and that silencing ZNF217 with siRNA restores sensitivity to doxorubicin. Moreover, elevated ZNF217 leads to increased phosphorylation of Akt, whereas inhibition of the phosphatidylinositol 3 kinase pathway and Akt phosphorylation decreases ZNF217 protein levels and increases sensitivity to doxorubicin. These results suggest that ZNF217 may promote neoplastic transformation by increasing cell survival during telomeric crisis and may promote later stages of malignancy by increasing cell survival during chemotherapy.

Original languageEnglish (US)
Pages (from-to)3219-3225
Number of pages7
JournalHuman Molecular Genetics
Volume14
Issue number21
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Telomere
Cell Death
Drug Therapy
Doxorubicin
Cell Survival
Phosphorylation
Kruppel-Like Transcription Factors
Phosphatidylinositol 3-Kinase
Breast Neoplasms
Proteins
Oncogenes
Cytogenetics
Small Interfering RNA
DNA Damage
Organism Cloning
Breast
Chromosomes
Epithelial Cells
Neoplasms

ASJC Scopus subject areas

  • Genetics

Cite this

Huang, G., Krig, S., Kowbel, D., Xu, H., Hyun, B., Volik, S., ... Collins, C. (2005). ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Human Molecular Genetics, 14(21), 3219-3225. https://doi.org/10.1093/hmg/ddi352

ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. / Huang, Guiqing; Krig, Sheryl; Kowbel, David; Xu, Hongmei; Hyun, Bill; Volik, Stas; Feuerstein, Burt G.F.; Mills, Gordon B.; Stokoe, David; Yaswen, Paul; Collins, Colin.

In: Human Molecular Genetics, Vol. 14, No. 21, 11.2005, p. 3219-3225.

Research output: Contribution to journalArticle

Huang, G, Krig, S, Kowbel, D, Xu, H, Hyun, B, Volik, S, Feuerstein, BGF, Mills, GB, Stokoe, D, Yaswen, P & Collins, C 2005, 'ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction', Human Molecular Genetics, vol. 14, no. 21, pp. 3219-3225. https://doi.org/10.1093/hmg/ddi352
Huang, Guiqing ; Krig, Sheryl ; Kowbel, David ; Xu, Hongmei ; Hyun, Bill ; Volik, Stas ; Feuerstein, Burt G.F. ; Mills, Gordon B. ; Stokoe, David ; Yaswen, Paul ; Collins, Colin. / ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. In: Human Molecular Genetics. 2005 ; Vol. 14, No. 21. pp. 3219-3225.
@article{5770fb77347e43db91f77f1603ef62c1,
title = "ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction",
abstract = "Chromosome 20q13.2 is amplified in 20-30{\%} of early-stage breast tumors and is associated with poor prognosis. Detailed mapping of the amplified region using molecular cytogenetics, positional cloning and genomic sequencing culminated in a detailed molecular description of the candidate oncogene ZNF217. ZNF217 proteins resemble Kruppel-like transcription factors, localize predominately to the nucleus and associate with proteins involved in transcriptional repression. The findings that ZNF217 can immortalize human mammary epithelial cells and that its amplification is associated with poor prognosis suggest that it may play roles in both early- and late-stage breast cancer. We present evidence that ZNF217 can attenuate apoptotic signals resulting from telomere dysfunction as well as from doxorubicin-induced DNA damage and that silencing ZNF217 with siRNA restores sensitivity to doxorubicin. Moreover, elevated ZNF217 leads to increased phosphorylation of Akt, whereas inhibition of the phosphatidylinositol 3 kinase pathway and Akt phosphorylation decreases ZNF217 protein levels and increases sensitivity to doxorubicin. These results suggest that ZNF217 may promote neoplastic transformation by increasing cell survival during telomeric crisis and may promote later stages of malignancy by increasing cell survival during chemotherapy.",
author = "Guiqing Huang and Sheryl Krig and David Kowbel and Hongmei Xu and Bill Hyun and Stas Volik and Feuerstein, {Burt G.F.} and Mills, {Gordon B.} and David Stokoe and Paul Yaswen and Colin Collins",
year = "2005",
month = "11",
doi = "10.1093/hmg/ddi352",
language = "English (US)",
volume = "14",
pages = "3219--3225",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "21",

}

TY - JOUR

T1 - ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction

AU - Huang, Guiqing

AU - Krig, Sheryl

AU - Kowbel, David

AU - Xu, Hongmei

AU - Hyun, Bill

AU - Volik, Stas

AU - Feuerstein, Burt G.F.

AU - Mills, Gordon B.

AU - Stokoe, David

AU - Yaswen, Paul

AU - Collins, Colin

PY - 2005/11

Y1 - 2005/11

N2 - Chromosome 20q13.2 is amplified in 20-30% of early-stage breast tumors and is associated with poor prognosis. Detailed mapping of the amplified region using molecular cytogenetics, positional cloning and genomic sequencing culminated in a detailed molecular description of the candidate oncogene ZNF217. ZNF217 proteins resemble Kruppel-like transcription factors, localize predominately to the nucleus and associate with proteins involved in transcriptional repression. The findings that ZNF217 can immortalize human mammary epithelial cells and that its amplification is associated with poor prognosis suggest that it may play roles in both early- and late-stage breast cancer. We present evidence that ZNF217 can attenuate apoptotic signals resulting from telomere dysfunction as well as from doxorubicin-induced DNA damage and that silencing ZNF217 with siRNA restores sensitivity to doxorubicin. Moreover, elevated ZNF217 leads to increased phosphorylation of Akt, whereas inhibition of the phosphatidylinositol 3 kinase pathway and Akt phosphorylation decreases ZNF217 protein levels and increases sensitivity to doxorubicin. These results suggest that ZNF217 may promote neoplastic transformation by increasing cell survival during telomeric crisis and may promote later stages of malignancy by increasing cell survival during chemotherapy.

AB - Chromosome 20q13.2 is amplified in 20-30% of early-stage breast tumors and is associated with poor prognosis. Detailed mapping of the amplified region using molecular cytogenetics, positional cloning and genomic sequencing culminated in a detailed molecular description of the candidate oncogene ZNF217. ZNF217 proteins resemble Kruppel-like transcription factors, localize predominately to the nucleus and associate with proteins involved in transcriptional repression. The findings that ZNF217 can immortalize human mammary epithelial cells and that its amplification is associated with poor prognosis suggest that it may play roles in both early- and late-stage breast cancer. We present evidence that ZNF217 can attenuate apoptotic signals resulting from telomere dysfunction as well as from doxorubicin-induced DNA damage and that silencing ZNF217 with siRNA restores sensitivity to doxorubicin. Moreover, elevated ZNF217 leads to increased phosphorylation of Akt, whereas inhibition of the phosphatidylinositol 3 kinase pathway and Akt phosphorylation decreases ZNF217 protein levels and increases sensitivity to doxorubicin. These results suggest that ZNF217 may promote neoplastic transformation by increasing cell survival during telomeric crisis and may promote later stages of malignancy by increasing cell survival during chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=27744434068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744434068&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddi352

DO - 10.1093/hmg/ddi352

M3 - Article

VL - 14

SP - 3219

EP - 3225

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 21

ER -